Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Suppan Christoph |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Wimmer, K; Hlauschek, D; Balic, M; Pfeiler, G; Greil, R; Singer, CF; Halper, S; Steger, G; Suppan, C; Gampenrieder, SP; Helfgott, R; Egle, D; Filipits, M; Jakesz, R; Sölkner, L; Fesl, C; Gnant, M; Fitzal, F
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST. 2025; 80: 103905
Doi: 10.1016/j.breast.2025.103905
Web of Science
FullText
FullText_MUG
Balic, M; Klocker, EV; Dobrić, N; Graf, R; Pancheri, L; Suppan, C; Jost, PJ; Heitzer, E; Dandachi, N
High-sensitivity detection and broad genomic profiling in HR+/HER2- breast cancer: Final comparative results using targeted single-gene and broad-panel sequencing assays.
The Journal of Liquid Biopsy Supplement: November 2024. 2024; 5(100190):-6th Annual Congress of Liquid Biopsy: “Advancing and Accelerating Access of Liquid Biopsy” (ISLB 2024); NOV 23-25, 2024; Denver, Colorado, USA.
[Poster]
FullText
Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
ctDNA profiling of HR+/HER2-low and HR+/HER2-0 metastatic breast cancer patients.
Molecular Oncology Supplement: EACR 2024: Innovative Cancer Science. 2024; 18(S1):i-ii.-EACR 2024 Congress: Innovative Cancer Science; JUN 10-13, 2024; Rotterdam, THE NETHERLANDS.
[Poster]
FullText
Dobrić, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients.
Proceedings of the 13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS). 2024; -13th International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS); MAR 4-6, 2024; Graz, AUSTRIA.
[Poster]
Klocker, EV; Dobrić, N; Suppan, C; Graf, R; Foldi, J; Heitzer, E; Oesterreich, S; Lee, AV; Jost, PJ; Dandachi, N; Balic, M
Comparison of lobular vs NST hormone receptor-positive
metastatic breast cancer patients in early lines of treatment via
comprehensive genomic profiling and whole-genome sequencing of
circulating tumor DNA.
Proceedings of the San Antonio Breast Cancer Symposium 2024; Abstract Number: SESS-1277
. 2024; -San Antonio Breast Cancer Symposium 2024; DEC 10-13, 2024; San Antonio, TX; USA.
[Poster]
FullText
Singer, CF; Hlauschek, D; Pfeiler, G; Egle, D; Bartsch, R; Suppan, C; Pichler, A; Petru, E; Greil, R; Rudas, M; Seifert, M; Petzer, A; Fitzal, F; Bago-Horvath, Z; Filipits, M; Soelkner, L; Fesl, C; Gnant, M
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial
J CLIN ONCOL. 2024; 42(16):
[Poster]
Web of Science
Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M
Sensitive detection of circulating tumor DNA using targeted capture sequencing in advanced HR+/HER2- breast cancer patients.
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE.
[Poster]
FullText
Dandachi, N; Graf, R; Pancheri, L; Dobric, N; Klocker, EV; Suppan, C; Jost, PJ; Heitzer, E; Balic, M
A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2-breast cancer patients
ANN ONCOL. 2023; 34: S1162-S1163.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN.
Doi: 10.1016/j.annonc.2023.09.1289
[Poster]
Web of Science
FullText
FullText_MUG
Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M
Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
ANN ONCOL. 2023; 34: S387-S387.-Annual Meeting of the European-Society-for-Medical-Oncology (ESMO); OCT 20-24, 2023; Madrid, SPAIN.
Doi: 10.1016/j.annonc.2023.09.667
[Poster]
Web of Science
FullText
FullText_MUG
Dobric, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Hasenleithner, S; Jost, PJ; Heitzer, E; Balic, M.
Comparison of ctDNA fraction and mutational profiles of plasma samples of HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
6th ACTC - Advances in Circulating Tumor Cells Book of Abstracts. 2023; -6th ACTC - Advances in Circulating Tumor Cells; SEP 20-23, 2023; Skiathos, GREECE.
[Poster]
FullText
Singer, CF; Konig, F; Kacerovsky-Strobl, S; Danzinger, S; Brunner, C; Suppan, C; Deutschmann, C; Balic, M; Greil, R; Egle, D; De Azambuja, E; Di Cosimo, S; Gnant, M
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial
J CLIN ONCOL. 2023; 41(16):
[Poster]
Web of Science
Wimmer, K; Hlauschek, D; Balic, M; Pfeiler, G; Strobl-Kacerovsky, S; Greil, R; Singer, CF; Halper, S; Steger, G; Suppan, C; Gampenrieder, SP; Helfgott, R; Egle, D; Filipits, M; Jakesz, R; Solkner, L; Fesl, C; Gnant, M; Fitzal, F
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
BREAST. 2023; 68: S123-S124.
[Poster]
Web of Science
Gampenrieder, SP; Rinnerthaler, G; Tinchon, C; Petzer, AL; Suppan, C; Heibl, S; Voskova, D; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Andel, J; Hubalek, M; Knauer, M; Greil, R
Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry
CANCER RES. 2021; 81(4):
[Poster]
Web of Science
Klocker, EV; Posch, F; Suppan, C; Mischitz, N; Dengler, L; Steiner, D; Müller, HD; Jost, P; Dandachi, N; Balic, M
Histopathological features and prognosis of early lobular breast cancer
Oncology Research and Treatment, Vol. 44, Suppl. 2, 2021. 2021; -Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie ; OCT 1-4, 2021; Berlin, GERMANY.
[Poster]
Rinnerthaler, G; Gampenrieder, SP; Tinchon, C; Petzer, AL; Suppan, C; Heibl, S; Voskova, D; Zabernigg, AF; Egle, D; Sandholzer, M; Singer, CF; Roitner, F; Andel, J; Hubalek, M; Knauer, M; Greil, R
First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry
CANCER RES. 2021; 81(4):
[Poster]
Web of Science
Suppan, C; Zhou, Q; Jahn, S; Graf, R; Klocker, EV; Terbuch, A; Kashofer, K; Posch, F; Gerritsmann, H; Dandachi, N; Heitzer, E; Balic, M
Comparison of liquid biopsy and tissue based detection of PIK3CAmutations in HR positive metastatic breast cancer patients
CANCER RES. 2021; 81(4):
[Poster]
Web of Science
Christoph Suppan, Qing Zhou, Stephan Jahn, Ricarda Graf, Eva Valentina Klocker, Angelika Terbuch, Karl Kashofer, Florian Posch, Hanno Gerritsmann, Nadia Dandachi, Ellen Heitzer, Marija Balic
Comparison of liquid biopsy and tissue based detection ofPIK3CAmutations in HR positive metastatic breast cancer patients.
SABCS 2020. 2020; -SABCS 2020; DEC 8-11, 2020; SAN ANTONIO, TEXAS, USA.
[Poster]
Singer, CF; Egle, D; Greil, R; Ohler, L; Petru, E; Suppan, C; Marhold, M; Pfeiler, G; Brunner, C; Tinchon, C; Halper, S; Galid, A; Pluschnig, U; Haslbauer, F; Hubalek, M; Redl, A; Flatschacher, J; Hennebelle, M; Mraz, B; Bartsch, R
REACHAUT: Real-world study of first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) in HR+, HER2-metastatic breast cancer (MBC).
ANN ONCOL. 2020; 31: S77-S78.-ESMO Breast Cancer Virtual Meeting; MAY 23-24, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.03.272
[Oral Communication]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Suppan, C; Steiner, D; Klocker, VE; Posch, F; Henzinger, EC; Stoeger, H; Dandachi, N; Balic, M
Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
J CLIN ONCOL. 2020; 38(15):
[Onlinepräsentation]
Web of Science
FullText
Suppan, C; Zhou, Q; Graf, R; Klocker, V; Terbuch, A; Dandachi, N; Heitzer, E; Balic, M
Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients.
ANN ONCOL. 2020; 31: S41-S41.-ESMO Breast Cancer Virtual Meeting; MAY 23-24, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.03.213
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
Balic, M; Suppan, C; Brcic, I; Tiran, V; Mueller, DH; Posch, F; Ulz, P; Heitzer, E; Dandachi, N
Untargeted assessment of tumour fractions in plasma for monitoring and prognostication from metastatic breast cancer patients undergoing systemic treatment
ANN ONCOL. 2019; 30: 110-+.-44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN.
[Poster]
Web of Science
Dandachi, N; Suppan, C; Brcic, L; Tiran, V; Mueller, DH; Posch, F; Ulz, P; Heitzer, E; Balic, M
Monitoring therapy response and assessing prognosis by untargeted FAST-SeqS of circulating tumor DNA in metastatic breast cancer patients
ONCOL RES TREAT. 2019; 42: 41-41.
[Poster]
Web of Science
Balic, M; Mueller, DH; Hammer, R; Gumpoldsberger, M; Suppan, C; Posch, F; Stoeger, H; Dandachi, N; Prein, K; Hauser, H; Lax, S
Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution
CANCER RES. 2018; 78(4):-San Antonio Breast Cancer Symposium; DEC 05-09, 2017; San Antonio, TX.
[Poster]
Web of Science
Muller, HD; Posch, F; Gumpoldsberger, M; Suppan, C; Hammer, R; Hauser, H; Dandachi, N; Prein, K; Stoger, H; Lax, S; Balic, M
Prognostic impact of the Residual Cancer Burden (RCB) index on recurrence-free survival of breast cancer patients recieving neoadjuvant therapy
ONCOL RES TREAT. 2018; 41: 297-298.
[Poster]
Web of Science
Suppan, C; Brcic, I; Heitzer, E; Tiran, V; Mueller, HD; Auer, M; Cote, RJ; Datar, R; Dandachi, N; Balic, M
Prognostic impact of tumor fractions in plasma assessed with mFAST-SeqS on overall survival of metastatic breast cancer undergoing systemic treatment
EUR J CANCER. 2018; 92: S136-S136.-11th European Breast Cancer Conference (EBCC); MAR 21-23, 2018; Barcelona, SPAIN.
[Poster]
Web of Science
Balic, M; Mueller, HD; Hammer,R; Gumpoldsberger, M; Suppan,C; Posch,F; Stoeger, H; Dandachi, N; Prein, K; Hauser, H; Lax, S;
Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution
Proceedings of the 40th San Antonio Breast Cancer Symposium Abstracts2View™ Portal. 2017; -SABACS; DEC 5-9 2017; San Antonio, USA.
[Poster]
FullText
Heitzer, E; ,Auer, M; Suppan, C; Dandachi, N; Balic, M.
Changes in ctDNA levels established with the untargeted
mFAST-SeqS method reflect response to therapy in
metastasized breast cancer patients
Proceedings of the 24EACR. 2017; -EACR; JUL 9-12, 2016; Manchester, UK.
[Poster]
FullText
Suppan, C; Tiran, V; Heitzer, E; Auer, M; Cote, RJ; Datar, RH; Dandachi, N; Balic, M
Serial blood draws in metastatic breast cancer patients undergoing systemic treatment analysed by size based CTC detection and mFAST Seq cell free DNA analysis
EUR J CANCER. 2017; 72: S39-S40.
Doi: 10.1016/S0959-8049(17)30211-3
[Poster]
Web of Science
FullText
FullText_MUG
Kump, P; Suppan, C; Spindelbock, W; Krejs, G; Lipp, R
Fifty-Three Year-Old-Male with a Symptomatic Ileocecal Carcinoid: An Individual Follow-Up of 14 Yrs with 5 Different Anti-Proliferative Therapies
NEUROENDOCRINOLOGY. 2015; 102(1-2):151-151.-12th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease; MAR 11-13, 2015; Barcelona, SPAIN.
[Poster]
Web of Science
Kump, PK; Spindelböck, W; Suppan, C; Ploner, F; Wießpeiner, U; Krejs, GJ; Lipp, R
53-jähriger Patient mit symptomatischem Ileocökalem Neuroendokrinem Tumor:14 Jahre Follow-Up sequentieller antiproliferativer Therapieoptionen
32. Jahrestagung der ACO-ASSO 2015 ; OCT 1-3, 2015; St. Wolfgang (Salzkammergut), AUSTRIA. 2015.
[Poster]
Suppan, C; Bauernhofer, T; Eisner, F; Stöger, H; Balic, M; Schöllnast, H; Liegl-Atzwanger, B;
Efficacy of sorafenib in a patient with metastatic high grade thymic carcinoma
ÖGHO Frühjahrstagung; APR 10-12, 2014; Innsbruck, AUSTRIA. 2014.
[Poster]
Suppan, C; Bjelic-Radisic, V; La Garde, M; Samonigg, H; Dandachi, N; Balic, M
N/L Ratio does not have predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy
EUR J CANCER. 2014; 50: S193-S193.-9th European Breast Cancer Conference (EBCC); MAR 19-21, 2014; Glasgow, SCOTLAND.
[Poster]
Web of Science
Suppan, C; Milkovic, L; Gasparovic, AC; Samonigg, H; Dandachi, N; Balic, M
Higher levels of HNE are associated with disease aggressiveness and worse outcome in breast cancer patients
EUR J CANCER. 2014; 50: S70-S70.-9th European Breast Cancer Conference (EBCC); MAR 19-21, 2014; Glasgow, SCOTLAND.
[Poster]
Web of Science
Suppan, C; Steger, G; Balic, M; Dandachi, N; Lang, A; Mlineritsch, B; Fesl,C; Samonigg, H; Gnat,M; Bauernhofer,T;
Evaluation of soluble E-Cadherin as a predictive marker for response to preoperative systemic chemotherapy in early breast cancer
Annals of Oncology Supplement 2014. 2014; -IMPAKT; May 7-10, 2014; Brussels, Belgium.
[Poster]
Bago-Horvath Z, Rudas M, Jakesz R, Greil R, Dietze O, Suppan C, Lax S, Singer CF, Filipits M, Gnant M.
Predictive value of intrinsic luminal subtypes in premenopausal women with endocrine-responsive early breast cancer: Results from Austrian breast and colorectal cancer study group trial 5
San Antonio Breast Cancer Symposium; DEC 10-14, 2013; San Antonio, Texas, USA. 2013.
[Poster]
Brunner, C; Jaeger, T; Suppan, C; Mueller-Holzner, E; Jasarevic, Z; Balic, M; Goebel, G; Marth, C; Stoeger, H; Samonigg, H; Hubalek,M; Lang, A;
Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis
ASCO 2013 Annual Meeting; MAY 31-JUNE 4, 2013; Chicago, USA. 2013.
[Poster]
Suppan, C; Bjelic-Radisic, V; La Guarde, M; Dandachi, N; Balic, M
Neutrophil/Lymphocyte Ratio does not have predictive or prognostic value in breast cancer patients undergoing neoadjuvant systemic therapy
ONKOLOGIE. 2013; 36: 158-158.
[Poster]
Web of Science
Suppan, C; Milkovic, L; Gasparovic, AC; Waeg, G; Dandachi, N; Balic, M
Higher levels of HNE are associated with disease aggressiveness and worse outcome of breast cancer patients
ONKOLOGIE. 2013; 36: 176-176.
Web of Science